Pharmacoeconomics of novel pharmacotherapies in triple-negative breast cancer-Reference-Cited by-同舟云学术

Pharmacoeconomics of novel pharmacotherapies in triple-negative breast cancer

Published:2023-04-11 Issue:7 Volume:24 Page:789-801
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Boscolo Bielo Luca¹²,Trapani Dario¹²^ORCID,Curigliano Giuseppe¹²^ORCID

Affiliation:

1. Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, Milan, Italy

2. Department of Oncology and Haematology, University of Milan, Milan, Italy

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2023.2201372

Reference71 articles.

1. Financial Burden of Cancer Care. Available 2022 Dec 4 from https://progressreport.cancer.gov/after/economic_burden.

2. Breast cancer overtakes lung cancer in terms of number of new cancer cases worldwide. IARC showcases key research projects to address breast cancer. (n.d.). Available 2022 Dec 26 from https://www.iarc.who.int/wp-content/uploads/2021/02/pr294_E.pdf.

3. Current and future burden of breast cancer: Global statistics for 2020 and 2040

4. Global challenges and policy solutions in breast cancer control

5. Triple-negative breast cancer molecular subtyping and treatment progress

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bruceine A: Suppressing metastasis via MEK/ERK pathway and invoking mitochondrial apoptosis in triple-negative breast cancer;Biomedicine & Pharmacotherapy;2023-12